Men's Health News

RSS

Young men take riskier decisions in presence of attractive women, study confirms

The presence of an attractive woman elevates testosterone levels and physical risk taking in young men, according to a recent study in the inaugural issue of Social Psychological and Personality Science (published by SAGE).

20 Mar 2010

Noscapine can be used as prophylactic treatment for prostate cancer: Study

New research has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer.

19 Mar 2010

Jail and fines for performing circumcision: Massachusetts Judiciary Committee rejects bill

A bill calling for prison time and fines for those who perform circumcision on any male under the age of 18 was rejected by the Judiciary Committee of the Massachusetts state legislature.

19 Mar 2010

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.

18 Mar 2010

Early baldness may not be associated with risk of prostate cancer

Men who start losing their hair at an early age may be less likely to develop prostate cancer in the future, new research suggests.

18 Mar 2010

Low T Center opens new men's testosterone diagnosis and treatment center in Southlake, Texas

Low T Center announces the grand opening of its new men's testosterone diagnosis and treatment center located at 601 Zena Rucker Road, Suite 101 – the corner of Byron Nelson Parkway and FM 1709 in Southlake, Texas. This is the first and only low testosterone therapy clinic for men in the Metroplex.

18 Mar 2010

Watchful waiting is viable option for many men with low risk prostate cancer

Active surveillance, also referred to as watchful waiting, is a viable option for many men with low risk prostate cancer although the concept continues to cause distress and confusion. James L. Mohler, MD, of Roswell Park Cancer Institute and chair of the NCCN Guidelines Panel for Prostate Cancer, discussed the role of active surveillance as well as other treatment options recommended in the recently updated NCCN Guidelines™ for Prostate Cancer at the NCCN 15th Annual Conference.

18 Mar 2010

High plasma selenium concentrations linked to lower occurrence of dysglycemia in elderly men

The role of selenium in diabetes has been controversial, with some studies suggesting that it raises diabetes risk and others finding that it is protective. Now, research published in BioMed Central's open access journal Nutrition and Metabolism, has shown that, for men, high plasma selenium concentrations are associated with a lower occurrence of dysglycemia.

18 Mar 2010

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Some of the most controversial issues in urology will be discussed by leading experts during the five-day 25th Annual Congress of the European Association of Urology in the Fira Barcelona congress venue in Barcelona (ES). From April 16 to 20, close to 12,000 participants and 3,000 company representatives are expected to gather in one of the world's biggest annual professional meetings in urology.

17 Mar 2010

Boosting radiation dose for prostate cancer patients does not increase severity of side effects

Boosting the radiation dose given to prostate cancer patients to a level that cut tumor recurrence in half did not increase the severity of side effects reported by patients up to a decade later. The study led by Massachusetts General Hospital Cancer Center researchers also found that patients characterized the impact of continuing side effects on their quality of life as considerably less bothersome than would be expected, based on earlier studies.

17 Mar 2010

Multimedia software program developed to help prostate cancer patients make treatment decisions

Mount Sinai School of Medicine is leading a study of patients newly-diagnosed with prostate cancer to determine if providing them with multimedia materials can help them make more informed treatment decisions. Michael Diefenbach, Ph.D., Associate Professor of Urology at Mount Sinai School of Medicine developed a multimedia software program designed to help prostate cancer patients and their families make treatment decisions.

15 Mar 2010

New SpermCheck Fertility home test kit for sperm level measurement

Infertility affects between 10 and 15 percent of couples worldwide. Surprisingly, problems with male fertility account for approximately 50 percent of infertility cases.

12 Mar 2010

New method to better study prostate cancer

Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.

12 Mar 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

PSA test is still the best option for diagnosing prostate cancer

When it comes to the documented 40 percent effectiveness of PSA testing in preventing death from prostate cancer, neither the American Cancer Society nor the discoverer of the PSA protein, Richard Ablin, are telling the public the complete story.

12 Mar 2010

Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review

The U.S. Food and Drug Administration has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

Study supports Myriad Genetics' PROLARIS molecular diagnostic test for predicting prostate cancer recurrence

Myriad Genetics, Inc. today said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS™, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. The abstract of the presentation entitled: "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy" by Gregory P. Swanson, M.D., University of Texas Health Science Center San Antonio, and colleagues is now available on the American Society of Clinical Oncology's website, www.asco.org.

11 Mar 2010

Genetic mutation in African-American men with family history of prostate cancer discovered

Shahriar Koochekpour, MD, PhD, Assistant Professor of Microbiology and Immunology, Biochemistry and Molecular Biology, and Genetics at LSU Health Sciences Center New Orleans, led research that has discovered, for the first time, a genetic mutation in African-American men with a family history of prostate cancer who are at increased risk for the disease.

11 Mar 2010

Imaging tools may help address challenging clinical dilemma of prostate cancer care: Study

New preliminary data from a pilot study in the Netherlands indicates that imaging tools may help address the most challenging clinical dilemma of prostate cancer care as identified by the hearing of the House Oversight and Government Reform Committee and its expert witnesses last week: to treat or not treat, AdMeTech Foundation's President and CEO Dr. Faina Shtern said today.

10 Mar 2010

Men's Health News

Young men take riskier decisions in presence of attractive women, study confirms

Noscapine can be used as prophylactic treatment for prostate cancer: Study

Jail and fines for performing circumcision: Massachusetts Judiciary Committee rejects bill

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

Early baldness may not be associated with risk of prostate cancer

Low T Center opens new men's testosterone diagnosis and treatment center in Southlake, Texas

Watchful waiting is viable option for many men with low risk prostate cancer

High plasma selenium concentrations linked to lower occurrence of dysglycemia in elderly men

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Boosting radiation dose for prostate cancer patients does not increase severity of side effects

Multimedia software program developed to help prostate cancer patients make treatment decisions

New SpermCheck Fertility home test kit for sperm level measurement

New method to better study prostate cancer

Genentech announces topline results from Phase III trial of Avastin

PSA test is still the best option for diagnosing prostate cancer

Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Study supports Myriad Genetics' PROLARIS molecular diagnostic test for predicting prostate cancer recurrence

Genetic mutation in African-American men with family history of prostate cancer discovered

Imaging tools may help address challenging clinical dilemma of prostate cancer care: Study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News